<DOC>
	<DOCNO>NCT02454699</DOCNO>
	<brief_summary>This phase I safety , PK food effect study CMV drug . In part 1 study , subject receive one four dosage strength MBX-400 ( 100 mg daily , 350 mg daily ; 750 mg daily ; 1000 daily ) 7 day safety PK assess . Subjects must 18 65 year age , male female ; female , surgically-sterilized post-menopausal ; male , undergone vasectomy ; body mass index ( BMI ) 18 32 kg/m^2 ; user nicotine-containing product ; willing abstain nicotine-containing product , alcohol illicit drug study . Subjects follow 28 day post dose .</brief_summary>
	<brief_title>Safety PK MBX-400 ( Cyclopropavir ) Normal Volunteers</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) common cause viral illness child adult . CMV also important congenital infection complication include deafness , developmental delay , cerebral palsy . The propose study design standard multiple ascend dose escalation study . Four cohort 8 subject ( 6 active ; 2 placebo ) enrol sequentially . MBX-400 administer orally daily 7 day , form capsule , study staff subject inpatient research unit . The study dose 100 , 350 , 750 , 1,000 mg daily . Up 32 healthy male female ( non-pregnant , non-lactating ) volunteer age 18-65 one site , consent allow participate study upon screen meet inclusion/exclusion criterion . Subjects enrol one four sequential cohort group : Cohort 1 receive 100 mg PO daily 7 day , Cohort 2 receive 350 mg PO daily 7 day , Cohort 3 receive 750 mg PO daily 7 day , Cohort 4 receive 1000 mg PO daily 7 day MBX-400 . Two member cohort receive placebo . The study duration subject expect approximately 80 day ( screen period , administration daily dose , follow-up ) . Each subject may admit unit 1 day prior first dose , remain unit day 7th daily dose . Subjects return follow-up visit last dose . Safety , tolerability , pharmacokinetics assess . The overall study duration across study group expect approximately 18 month . The primary objective evaluate safety tolerability multiple ascending dose 100 , 350 , 750 , 1000 mg PO daily 7 day MBX-400 healthy subject . The secondary objective determine plasma urine pharmacokinetic profile multiple dose 100 , 350 , 750 , 1000 mg PO daily 7 day MBX-400 healthy subject .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>1 . Subject able provide inform consent ; 2 . Subject age 18 65 year age , inclusive ; 3 . Good general health judge investigator ; 4 . Body Mass Index ( BMI ) 18 32 kg/m^2 ; 5 . Males females either capability sexual behavior could result father conceive child future ; Meeting inclusion criterion would demonstrate one parameter : Surgical sterilization ( vasectomy , tubal ligation , hysterectomy ) Females postmenopausal , define absence menstrual period great one year age 45 without alternate diagnosis ( e.g. , PCOS ) Absence heterosexual activity except partner meet one criterion ; 6 . Available willing participate study procedures requirement ; Able willing stay clinical facility 10 day return visit ; swallow capsule provide ; blood urine collection duration study . 7 . Nonsmoker , former smoker , former userc nicotinecontaining product Former smoker/user define someone smoke used nicotineproducts one time week least one month smoke least 3 month use nicotinecontaining product least 1 month willing abstain nicotinecontaining product study ; 8 . Willing abstain alcohol Day 10 visit* moderate drinking study end ( less equal 2 drinks/day ) . Illicit drug use throughout study ; *the completion PK collection 9 . Demonstrates knowledge comprehension study pass questionnaire study protocol score least 70 % . Anyone pass test initially may retake test . 1.Have acute illness and/or oral temperature &gt; 100.4°F ( 38°C ) within three day prior drug dosing ; 2.Have medical disease condition , opinion site principal investigator appropriate subinvestigator , contraindication study participation ; Including acute chronic medical disease condition , would place subject unacceptable risk injury , render subject unable meet requirement protocol , may interfere evaluation response subject 's successful completion study . 3.Have known allergy component MBX400 placebo capsule ( microcrystalline cellulose , gelatin , titanium dioxide ) ; 4.Have history anaphylaxis serious adverse reaction nucleoside analog medication ; 5.Have active malignancy history metastatic hematologic malignancy ; 6.Have clinically significant abnormal ECG screening base ECG reading predefined study consult cardiologist ; Including : 1 ) conduction disturbance ( complete leave complete right bundle branch block nonspecific intraventricular conduction disturbance QRS &gt; / =120ms , PR &gt; / =220ms , second third degree AV block , QTc prolongation ( &gt; 450ms ) ; 2 ) significant repolarization ( ST segment T wave ) abnormality ; 3 ) significant atrial ventricular arrhythmia ; 4 ) frequent atrial ventricular ectopy ( e.g. , frequent premature atrial contraction , 2 premature ventricular contraction row ) ; 5 ) ST elevation consistent ischemia ; 6 ) evidence past evolve myocardial infarction 7.Have know currently active HIV , CMV , hepatitis B hepatitis C infection ; 8.Have clinically significant anemia bleed disorder ; 9.Have clinically significant gastrointestinal disorder include ulcer disease condition affect absorption ; 10.Have blood pressure heart rate Grade &gt; / =1 ; 11.Have total White Blood Cell ( WBC ) count , Absolute Neutrophil Count ( ANC ) , hemoglobin platelet count Grade &gt; / =1 screening ; 12.Have creatinine high normal range screening ; 13.Have Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; Upper Limit Normal screening ; 14.Have PT PTT Grade &gt; / =1 screening ; 15.Have electrolyte level ( sodium , potassium ) Grade &gt; / =1 screening ; 16.Have value high trace glucose , hemoglobin and/or protein urinalysis screening ; 17.Have ongoing drug abuse/dependence ( include alcohol ) history within five year enrollment ; 18.Have diagnosis , current past , schizophrenia , bipolar disease , major psychiatric diagnosis ; 19.Have history hospitalization psychiatric illness , suicide attempt , confinement danger self others , within past 10 year ; Subjects psychiatric disorder meeting exclusion criterion , e.g. , attentiondeficit hyperactivity disorder , control minimum 3 month may enrol long investigator determine subject 's mental status compromise subject 's ability comply protocol . 20.Have donate blood within 30 day prior Day 1 plan donate blood study ; 21.Have take drug active herpes virus within 30 day prior Day 1 include limit : acyclovir , valacyclovir , famciclovir , penciclovir , ganciclovir valganciclovir ; 22.Use medication chronic basis ; 23.Use alcoholcontaining , grapefruitcontaining , caffeinecontaining food beverage within 72 hour prior Checkin ( Day 1 ) ; 24 . Are take utilized drug within 3 day prior Day 1 ; alcohol tobacco within 3 day prior Day 1 ; chronic alcohol user ; Concomitant medication , include prescription counter medication well herbal , vitamin supplement , allow within 3 day prior Day 1 . Chronic alcohol user define consume 10 alcoholic drink per week . 25.Urine cotinine level &gt; 150 ng/mL ; 26.Have take investigational agent within 28 day Day 1 ; 27.Have positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 15, 2016</verification_date>
	<keyword>antiviral</keyword>
	<keyword>ascend dose</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>food effect</keyword>
	<keyword>Herpesviridae</keyword>
	<keyword>MBX-400</keyword>
</DOC>